symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
VOR,2.37,-0.726107,87720,160066728,0,1.89-7.57,0.15,Vor Biopharma Inc.,USD,0001817229,US9290331084,929033108,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.vorbio.com,"Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.","Dr. Robert  Ang M.B.A., M.D., MBBS",Healthcare,US,133,617 655 6580,100 Cambridgepark Drive,Cambridge,MA,02140,,0,https://financialmodelingprep.com/image-stock/VOR.png,2021-02-05,False,False,True,False,False
